Now let me do calibration searches to anchor the score.Now I have enough information to write the consolidated review. Let me also check the closest low-scoring calibration paper quickly.Now I have sufficient information to write the final consolidated review.

---

## Summary

This paper proposes a dual-metric model selection procedure for self-supervised learning (SSL) of vision transformers in computational histopathology. The procedure combines task-specific benchmark metrics (classification accuracy, segmentation AJI on publicly available histopathology datasets) with task-agnostic representation quality metrics (RankMe, LiDAR, α-ReQ) to identify optimal training checkpoints across three modes: classification-best (e_c*), segmentation-best (e_s*), and all-round (e_a*). Nine DINOv1 models varying in architecture and magnification are trained on LUAD data, with a key empirical finding that training for longer is detrimental—optimal checkpoints occur mid-training—and that segmentation and classification tasks peak at different epochs.

---

## Strengths

- **Training saturation is a concrete, cross-model empirical finding (Figure 2, Table 2):** Across all nine model configurations, the final-epoch checkpoint consistently underperforms the selected checkpoints, and training loss continues to decrease even as downstream task performance degrades. This challenges the default practice of running SSL to convergence and provides actionable guidance for practitioners.

- **Divergent optimal epochs for segmentation vs. classification (Figure 2, §5.1):** The paper concretely shows that e_s* (segmentation-best) occurs systematically earlier in training than e_c* (classification-best), with e_a* aligning closely with e_s*. Figure 3's scatter plots of task-agnostic vs. task-specific metrics also reveal that rank-based metrics track classification but diverge from segmentation performance, a specific mechanistic observation.

- **Competitive segmentation performance (Table 2):** Several small-scale models match or outperform foundation models on PanNuke 20× and MoNuSeg (e.g., ViT-S SMoE-32 e_s* achieves 0.60 AJI on MoNuSeg vs. Virchow2's 0.58), despite being trained on a single cancer type with orders of magnitude less data. This is a practically significant result for the histopathology community.

- **Architecture diversity (Table 1):** Nine models spanning ViT-S, ViT-B, and three SMoE variants across multiple magnification configurations provide reasonable robustness to architecture-specific confounds for the saturation finding.

- **Independent held-out validation in §5.3:** EGFR classification and LUAD subtyping were explicitly withheld from the selection procedure, providing at least partial independent validation.

---

## Weaknesses

### Fatal
None.

### Major

- **The contribution of task-agnostic metrics is never isolated (Algorithm 1 design gap).** This is the central methodological issue. Algorithm 1 uses task-agnostic metrics to generate a candidate epoch set S (step 3–4), but the final selection (step 5–6) is done entirely by maximising the sum of task-specific metrics across candidate epochs. This means task-agnostic metrics only serve as a filter to pre-select candidates, and the final answer is driven purely by benchmark performance. The paper never shows that this procedure is superior to the simplest baseline: pick the epoch with the highest average task-specific benchmark score. Since all benchmark evaluations are already performed at every checkpoint, this baseline is free to run and would directly establish whether the task-agnostic filtering genuinely contributes anything. Without this ablation, the paper cannot support its core claim that combining task-agnostic with task-specific metrics is the key contribution. The stated motivation—that task-agnostic metrics could reduce the need for expensive benchmark evaluation—is further undermined by the fact that Algorithm 1 still requires all benchmark evaluations to run.

- **Self-referential Table 2 evaluation weakens the performance narrative.** The selection benchmarks (BACH, CRC, MHIST, PanNuke, MoNuSeg) are identical to the Table 2 evaluation datasets. While the final-checkpoint vs. selected-checkpoint comparison in Table 2 IS valid (the final epoch is not chosen by the algorithm), the headline claim that "selected checkpoints outperform" must be understood as in-sample for those benchmarks. The genuinely independent evaluation is §5.3, but as noted below, the effect sizes there are negligible.

- **Held-out evaluation shows negligible differentiation (Figure 4).** In §5.3—the only evaluation that is truly independent of the selection procedure—the three checkpoint types yield nearly indistinguishable AUC values for both EGFR classification and LUAD subtyping. The paper acknowledges this ("AUC performance values do not substantially deviate between checkpoint types") but interprets it as corroboration rather than a null result. No variance estimates or confidence intervals are reported across the 10 splits, making it impossible to assess statistical significance. This is the primary validation of the practical value of the approach, and it does not provide convincing differentiation.

### Minor

- **Overstated "comparable to foundation models" claim for classification tasks.** The BACH gap between the best paper model (0.71) and Virchow2 (0.80) is ~9 percentage points, which is not "comparable" by any reasonable standard. The competitive performance claim holds for segmentation tasks, but the conclusion (§6) and §5.2 narrative elide this distinction.

- **DINOv1-specific training dynamics conflated with histopathology-specific findings.** The conclusion states "training for longer is often detrimental to generalization…in sharp contrast to observations from other data modalities." DINOv1 is known to exhibit instability and plateau-then-collapse dynamics at long training schedules, which may fully explain the saturation finding. The paper does not test whether this holds for DINOv1v2-based models. Since the paper explicitly scopes to DINOv1, this is a minor point, but the generalization phrasing in §6 is too strong.

- **Task-agnostic metrics acknowledged as ill-suited for segmentation but still used for e_s*.** The paper correctly notes in §2.2 that rank-estimation metrics "may not be adequate for inherently non-linear tasks such as multiple instance learning," and Figure 3 empirically confirms poor correlation between rank metrics and segmentation performance. Yet the segmentation-best selection (e_s*) still incorporates these metrics in generating the candidate set S. The mismatch between acknowledged limitation and actual usage is not reconciled methodologically.

### Trivial
None beyond formatting artifacts already excluded.

---

## Nice-to-Haves

- An ablation comparing Algorithm 1's output to the naive baseline (epoch with highest average task-specific benchmark score) would directly establish whether task-agnostic metrics add value. All data already exists; this experiment is costless.
- Statistical reporting (mean ± std) across the 10 train/test splits in Figure 4 would clarify whether Figure 4 differences, however small, are consistent.
- A brief replication on a single DINOv2-trained model or a second tissue type would strengthen the generalizability claim beyond DINOv1/LUAD.

---

## Removed Points

*These points are flagged to be removed, treat them with caution.*

- **"Existence/availability of foundation models" concern:** No reviewer raised this; no removal needed.
- **Harsh Critic §5.2 "architecturally imbalanced comparison" concern (Virchow2 uses ViT-H, DINOv2):** Removed per hard rule — asymmetry favors the baseline (foundation models), not the authors. The authors presenting results where their smaller model matches larger ones is a valid and honest comparison.
- **Generic "the scope is too narrow" concern (single tissue, single SSL):** The paper explicitly scopes to DINOv1 and LUAD in §1.3. This is a legitimate limitation but not a fatal flaw; it is reflected under Minor.
- **Harsh Critic's claim about MHIST exclusion being undisclosed:** The exclusion is noted in a table footnote (Table 2), which is sufficient disclosure. This is a trivial presentation point removed per soft rules.
- **Strength Finder claim about "Formal Algorithm 1 as a key strength":** Generic — any paper with an algorithm has a formal algorithm. Dropped.
- **Strength Finder claim about "code and data release":** Generic across the field; not paper-specific evidence of quality. Dropped.

---

## Novel Insights

The clearest novel empirical insight is that in DINOv1-trained histopathology models, instance segmentation performance peaks earlier in training than classification performance, and this divergence is detectable via scatter plots of rank-based task-agnostic metrics vs. task-specific benchmark scores. This observation—that the SSL training phase that maximizes representational rank does not coincide with the phase that maximizes segmentation task performance—is concrete and practically actionable for the histopathology community. The finding that training loss continues to decrease while downstream task performance degrades adds to this picture. The methodological vehicle (dual-metric Algorithm 1) for exploiting this observation is less novel and less rigorously validated than the observation itself.

---

## Suggestions

1. **Run the free ablation:** Compare Algorithm 1 output vs. "pick highest average benchmark epoch" on all nine models. Report how often the two procedures select different epochs, and whether the dual-metric selection shows any performance advantage on the held-out §5.3 tasks.
2. **Add error bars to Figure 4:** With 10 splits, this is straightforward and would either confirm the null or surface real differentiation.
3. **Separate the empirical finding from the selection procedure claim:** The saturation and task-type-divergence findings are strong on their own. Framing the paper more explicitly as an empirical study of training dynamics with a practical selection heuristic—rather than a validated selection system—would better match the evidence level.
4. **Revise the "comparable to foundation models" language** to restrict the claim to segmentation benchmarks, where it is actually supported.

---

## Score and Decision

**Calibration anchors:**

| Paper | Path | Avg Score | Comparison |
|---|---|---|---|
| Masked Mamba for pathology SSL | `V9UsZBbTvZ.md` | 3.0 | Low anchor; rejected for limited novelty, pure architecture proposal in histopathology SSL — this paper has more original empirical insight but similar scope limitations |
| FroSSL (SSL method) | `1mOeklnLf4.md` | 3.5 | Low anchor; simple SSL objective, insufficient novelty — weaker than this paper |
| Self-Supervision Is Not All You Need | `nnYsWoe1ST.md` | 4.0 | Low-medium anchor; empirical study of SSL vs. semi-supervised, rejected for incremental empirical contribution without clear methodological advance — directly comparable in structure |
| Early Stopping Criteria in HPO | `Zihqr7qqpg.md` | 4.67 | Medium-low anchor; systematic study on early stopping, most conceptually similar — rejected for unclear contribution and limited baselines |
| Weakly Supervised Virus Capsid Detection | `RJDjSXNuAZ.md` | 5.5 | Medium anchor; domain-specific application paper accepted at poster — more methodologically complete |
| VLSA (survival analysis in pathology) | `trj2Jq8riA.md` | 5.67 | Medium anchor; accepted pathology paper with clear improvement over baselines |
| CAMIL (MIL for WSI) | `rzBskAEmoc.md` | 7.5 | High anchor; strong pathology paper with significant validated improvements — this paper falls far short in terms of validated performance gains |
| PathGen-1.6M | `rFpZnn11gj.md` | 7.5 | High anchor; large-scale pathology contribution — clearly stronger than this paper |

**Assessment:** The paper's core empirical finding (training saturation, task-type divergence of optimal epochs) is useful and concrete, placing it above the purely-low-scoring papers (3.0–3.5). However, the missing key ablation (task-agnostic value over task-specific-only baseline) and the negligible differentiation in the only independent evaluation (§5.3) prevent it from reaching the medium-accepted range (~5.5). The paper most closely resembles the early-stopping HPO study (avg 4.67) and the SSL empirical study (avg 4.0), both of which were rejected. Given these anchors, and that the missing ablation is an inexpensive experiment that directly undermines the core methodological claim, the paper falls below acceptance bar.

**Score: 4.0 | Decision: Reject**

MY FINAL SCORE: <pineapple>4.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>